Endophilin A2, a Potential Therapeutic Target for Lupus, Promotes Lupus Progression

Area of Science:

• Immunology
• Molecular Biology
• Pathogenesis of Autoimmune Diseases

Background:

• Endophilin A2 (EPA2) is a protein implicated in cellular processes, but its role in systemic lupus erythematosus (SLE) pathogenesis remains largely unknown.
• Understanding the molecular mechanisms underlying SLE is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the association between Endophilin A2 (EPA2) and the pathogenesis of systemic lupus erythematosus (SLE).
• To explore the potential role of EPA2 in angiogenesis and its regulation by GDF15 in the context of SLE.

Main Methods:

• Quantified plasma and mRNA levels of EPA2 in SLE patients and healthy controls using ELISA and qRT-PCR.
• Utilized a pristane-induced lupus mouse model, administering EPA2 siRNA adenovirus to assess histological and serological changes.
• Investigated the in vitro effects of EPA2 siRNA on human umbilical vein endothelial cells (HUVECs) in the presence and absence of GDF15, evaluating cell proliferation, migration, and tube formation.

Main Results:

• Plasma and mRNA levels of EPA2 were significantly elevated in SLE patients compared to healthy controls.
• Lupus mice exhibited characteristic disease features, including splenomegaly, tissue damage, and high autoantibody levels, which were attenuated by EPA2 siRNA treatment.
• EPA2 knockdown in HUVECs reduced GDF15 expression and impaired angiogenesis, while GDF15 co-treatment reversed these effects, enhancing endothelial cell function.

Conclusions:

• Endophilin A2 (EPA2) plays a significant role in SLE pathogenesis, potentially by modulating angiogenesis through its interaction with GDF15.
• Targeting EPA2 may represent a novel therapeutic strategy for managing SLE and related autoimmune conditions.